Rhythm Pharmaceuticals, Inc. RYTM Convertible Debt - Current

Convertible Debt - Current at other companies

HubSpotHUBS

$368.88M—

Schering-PloughSGP

$204.54M+182%

Circle Internet Group, Inc.CRCL

$0-100%

Affirm Holdings, Inc.AFRM

$1.13B-2.0%

Mirum Pharmaceuticals, Inc.MIRM

$310.25M+0.6%

SalesforceCRM

$0—

Other financials

Income statement

See full

Revenue$60.1M+83.8%

Gross profit$53.0M+82.3%

Operating income-$52.4M-11.4%

Net income-$55.6M-12.4%

EPS (diluted)-$0.83-2.5%

Balance sheet

See full

Cash & equivalents$62.1M-41.4%

Total debt$112.3M-1.1%

Total equity$122.9M+549%

Total assets$442.3M+14.4%

Cash flow

See full

Operating cash flow-$44.2M-9.5%

CapEx$238.3K—

Free cash flow-$29.2M-2.4%

Valuation

See full

Market cap$6.64B+77.3%

Enterprise value$6.69B+78.4%

P/S30.6×+3.2×

Profitability

See full

Gross margin89.4%-0.2pp

Operating margin-90.9%-19.8pp

Net margin-93.3%-18.2pp

FCF margin-61.5%-14.1pp

Returns & leverage

See full

Return on equity-285.8%-68.9pp

Debt / equity0.9×-5.1×

Current ratio4.2×+0.9×

Where this comes from

Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:TemporaryEquityCarryingAmountAttributableToParent.

The official record: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rhythm Pharmaceuticals, Inc.'s convertible debt - current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Rhythm Pharmaceuticals, Inc.'s convertible debt - current?: Rhythm Pharmaceuticals, Inc. (RYTM) reported convertible debt - current of $114.71M in Q1 2026.